Angiotensin receptor blocker use and gastro‐oesophageal cancer survival: a population‐based cohort study

Angiotensin receptor blockers (ARBs; including candesartan, losartan, olmesartan and valsartan) are widely used to treat hypertension, heart failure and diabetic neuropathy. There is considerable pre‐clinical evidence that ARBs can reduce cancer progression, particularly for gastric cancer. Despite this, epidemiological studies have yet to assess the impact of ARB use on gastro‐oesophageal cancer survival.

[1]  A. B. Hill.  The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[2]  R Simon,et al.  A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.

[3]  C. Jacobi,et al.  Quality of life following resection of oesophageal carcinoma , 1996, The British journal of surgery.

[4]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[5]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[6]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[7]  I. Armando,et al.  Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[8]  C. Nahmias,et al.  Angiotensin receptors: a new role in cancer? , 2005, Trends in Endocrinology & Metabolism.

[9]  P. Malfertheiner,et al.  The Number of Lymph Node Metastases in Gastric Cancer Correlates with the Angiotensin I–Converting Enzyme Gene Insertion/Deletion Polymorphism , 2005, Clinical Cancer Research.

[10]  J. Lagergren,et al.  Quality of life and persisting symptoms after oesophageal cancer surgery. , 2006, European journal of cancer.

[11]  Jaclyn H Neo,et al.  Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases , 2007, Journal of gastroenterology and hepatology.

[12]  J. LeLorier,et al.  Application of lag‐time into exposure definitions to control for protopathic bias , 2007, Pharmacoepidemiology and drug safety.

[13]  S. Cai,et al.  Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. , 2008, Chinese medical journal.

[14]  G. Mancia,et al.  Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy , 2008, Journal of Hypertension.

[15]  Georg Petroianu,et al.  Captopril as a Potential Inhibitor of Lung Tumor Growth and Metastasis , 2008, Annals of the New York Academy of Sciences.

[16]  J. Kinoshita,et al.  Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. , 2009, International journal of oncology.

[17]  D. Rowland,et al.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. , 2010, The Lancet. Oncology.

[18]  Samy Suissa,et al.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes , 2010, BMJ : British Medical Journal.

[19]  M. Alan Brookhart,et al.  Healthy User and Related Biases in Observational Studies of Preventive Interventions: A Primer for Physicians , 2011, Journal of General Internal Medicine.

[20]  C. Yeo,et al.  Blocking Angiotensin II Type 1 Receptor Triggers Apoptotic Cell Death in Human Pancreatic Cancer Cells , 2010, Pancreas.

[21]  M. Lipsitch,et al.  Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies , 2010, Epidemiology.

[22]  R. Hannan,et al.  The renin–angiotensin system and cancer: old dog, new tricks , 2010, Nature Reviews Cancer.

[23]  T. Blakely,et al.  Measuring cancer survival in populations: relative survival vs cancer-specific survival. , 2010, International journal of epidemiology.

[24]  R. Perera,et al.  Adaptation and validation of the Charlson Index for Read/OXMIS coded databases , 2010, BMC family practice.

[25]  C. Hughes,et al.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review , 2011, Cancer Causes & Control.

[26]  R. Steele,et al.  Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? No , 2011, BMJ : British Medical Journal.

[27]  L. Ruilope,et al.  Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. , 2011, European heart journal.

[28]  S. Fagan,et al.  Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. , 2011, Clinical science.

[29]  M. Hongo,et al.  Combination of angiotensin II receptor blockers promotes proton pump inhibitor-based healing of reflux esophagitis , 2012, Journal of Gastroenterology.

[30]  Sang Min Park,et al.  Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies , 2011, Canadian Medical Association Journal.

[31]  S. Kjeldsen,et al.  Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. , 2011, The Lancet. Oncology.

[32]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[33]  S. Bojesen,et al.  Statin use and reduced cancer-related mortality. , 2012, The New England journal of medicine.

[34]  S. Oh,et al.  How Does Inhibition of the Renin-Angiotensin System Affect the Prognosis of Advanced Gastric Cancer Patients Receiving Platinum-Based Chemotherapy? , 2012, Oncology.

[35]  Y. Yamaoka,et al.  Role of renin‐angiotensin system in gastric oncogenesis , 2012, Journal of gastroenterology and hepatology.

[36]  P. Angus,et al.  Review article: the pathophysiological roles of the renin–angiotensin system in the gastrointestinal tract , 2012, Alimentary pharmacology & therapeutics.

[37]  K. Chalkidou.  About the National Institute for Health and Care Excellence - NICE. , 2013, Acta medica portuguesa.

[38]  N. Weiss,et al.  Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. , 2013, Journal of the National Cancer Institute.

[39]  G. Savoye,et al.  Olmesartan‐associated enteropathy: results of a national survey , 2014, Alimentary pharmacology & therapeutics.

[40]  Mingmin Huang,et al.  Angiotensin II promotes the progression of human gastric cancer. , 2014, Molecular medicine reports.

[41]  J. Kinoshita,et al.  The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. , 2014, Cancer letters.

[42]  K. Rau,et al.  Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[43]  David B Richardson,et al.  The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application , 2015, Current Epidemiology Reports.

[44]  K. Bhaskaran,et al.  Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.

[45]  P. Elwood,et al.  Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies , 2016, PloS one.

[46]  C. Choi,et al.  The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis , 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.